No Data Yet
Terns Pharmaceuticals' stock surged 50% after its once-daily leukemia pill demonstrated a 99% reduction in cancer cell counts in nearly three-fourths of patients during an early-phase trial.
Arcellx and partner Kite (Gilead) announced strong Phase 2 data for their multiple myeloma CAR-T therapy, anito-cel, showing high response rates and durable efficacy. The results, presented at the ASH Annual Meeting, intensify competition in the crowded cell therapy market.